Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (81-90 of 179) with videos related to

Pageof 18
Sort By:
Cancer|February 27, 2020
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomesFevzi F Yalniz, Keyur P Patel, Qaiser Bashir, et al.
Blood|November 6, 2007
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinibJamshid S Khorashad, Dragana Milojkovic, Puja Mehta, et al.
Blood|February 29, 2012
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantationAristeidis Chaidos, Scott Patterson, Richard Szydlo, et al.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Cancer|March 22, 2017
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioningOrhan Kemal Yucel, Rima M Saliba, Gabriella Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2011
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedureKatayoun Rezvani, Edward J Kanfer, David Marin, et al.
Blood|March 23, 2010
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phaseJirí Pavlů, Andrea K Kew, Beatrice Taylor-Roberts, et al.
Blood|August 22, 2008
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorDavid Marin, Dragana Milojkovic, Eduardo Olavarria, et al.
Haematologica|February 4, 2014
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemiaKate Stringaris, Takuya Sekine, Ahmad Khoder, et al.
The American Journal on Addictions|September 16, 2016
Prevalence and correlates of cannabis use among athletes-A systematic reviewMaria Beatriz Brisola-Santos, João Guilherme de Mello E Gallinaro, Felipe Gil, et al.
Pageof 18

Showing results (81-90 of 179) with videos related to

Sort By:
Pageof 18
Cancer|February 27, 2020
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomesFevzi F Yalniz, Keyur P Patel, Qaiser Bashir, et al.
Blood|November 6, 2007
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinibJamshid S Khorashad, Dragana Milojkovic, Puja Mehta, et al.
Blood|February 29, 2012
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantationAristeidis Chaidos, Scott Patterson, Richard Szydlo, et al.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Cancer|March 22, 2017
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioningOrhan Kemal Yucel, Rima M Saliba, Gabriella Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2011
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedureKatayoun Rezvani, Edward J Kanfer, David Marin, et al.
Blood|March 23, 2010
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phaseJirí Pavlů, Andrea K Kew, Beatrice Taylor-Roberts, et al.
Blood|August 22, 2008
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorDavid Marin, Dragana Milojkovic, Eduardo Olavarria, et al.
Haematologica|February 4, 2014
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemiaKate Stringaris, Takuya Sekine, Ahmad Khoder, et al.
The American Journal on Addictions|September 16, 2016
Prevalence and correlates of cannabis use among athletes-A systematic reviewMaria Beatriz Brisola-Santos, João Guilherme de Mello E Gallinaro, Felipe Gil, et al.
Pageof 18